Nina Shah, MD

Nina Shah is the Global Head of Multiple Myeloma Clinical Development and Strategy in the Hematology Research & Development Department at AstraZeneca. Prior to this she was a Professor of Clinical Medicine in the Division of Hematology-Oncology at University of California San Francisco. Her career has been centered on multiple myeloma, from MGUS to relapsed/refractory disease. Dr. Shah’s research has focused on multiple myeloma clinical trials, specifically immunotherapy and cellular therapy. She is also interested in outcomes research for myeloma patients undergoing autologous transplantation/ cellular therapy and led a randomized trial to determine the impact of stem cell dose on symptoms in this patient population. Dr. Shah has been heavily involved in the myeloma research community and led the effort to define myeloma-transplant practice guidelines for the American Society of Transplantation and Cellular Therapy (ASTCT). She also served as a Co-Chair for the Plasma Cell Disorders and Adult Solid Tumors Working Committee at the Center for International Blood & Marrow Transplant Research (CIBMTR) and is a former chair of the American Society of Hematology Scientific Committee on Plasma Cell Neoplasia.